Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitors of SARS-CoV‑2 Entry: Current and Future Opportunities

15 Jun 2020

Abstract excerpt

Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2 has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological agent of "coronavirus disease 2019", abbreviated to COVID-19, which despite only being identified at the very end of 2019, has now been classified as a pandemic by the World Health Organization (WHO). At this time, no specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32539378
DOI: 10.1021/acs.jmedchem.0c00502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitors of SARS-CoV‑2 Entry: Current and Future OpportunitiesPMID 32539378Read ↗

Anti-viral chimeric protein RetroMAD1™ potently block SARS-CoV-2 viral entry and propagationSemantic proximity Read ↗

Recent advances in small-molecular therapeutics for COVID-19Semantic proximity Read ↗

Identification of Potent Small Molecule Inhibitors of SARS-CoV-2 EntrySemantic proximity Read ↗

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.Semantic proximity Read ↗

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host CellsSemantic proximity Read ↗

Novel Drugs Targeting the SARS-CoV-2/COVID-19 MachinerySemantic proximity Read ↗

Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitorsSemantic proximity Read ↗

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorSemantic proximity Read ↗

TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)Semantic proximity Read ↗

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment StrategiesSemantic proximity Read ↗

Structural biology of SARS-CoV-2: open the door for novel therapiesSemantic proximity Read ↗

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.